ArticleActa Cardiologica Sinica2026
Epicardial Fragmentation Mapping in Brugada Syndrome: A Three-Patient Case Series with Literature Review.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brugada syndrome (BrS) carries a high risk of ventricular fibrillation (VF) despite protective therapy with implantable cardioverter-defibrillators (ICDs). Catheter ablation targeting epicardial substrate in the right ventricular outflow tract (RVOT) has emerged as a promising adjunctive strategy; however, optimal procedural endpoints remain unclear. Objective: To present a case series of three BrS patients who underwent high-density (HD) epicardial substrate ablation assisted by electrogram fragmentation mapping, and to review contemporary evidence on Brugada substrate ablation. Methods: Three symptomatic BrS patients underwent epicardial HD mapping using the EnSite X three-dimensional mapping system and Advisor HD Grid catheter. A dedicated fractionation mapping algorithm was used to identify regions of abnormal electrograms. All spontaneous fractionated or late potentials were ablated until the fragmentation map showed no residual abnormal points. Results: In our three cases, HD mapping localized clusters of low-voltage, fractionated electrograms in the RVOT epicardium, which were successfully eliminated with epicardial radiofrequency ablation. Complete substrate removal resulted in normalization of the Brugada electrocardiographic pattern in all patients and rendered VF non-inducible. Over 6 months of follow-up, no VF recurrence was noted and no ICD therapies were delivered. No major procedural complications were observed. Post-ablation voltage maps remained patchy (reflecting residual scar tissue); however, the fragmentation maps became uniformly clean, supporting their utility as an objective endpoint. Conclusions: This case series demonstrates the feasibility of using fragmentation mapping as an intra-procedural guide and endpoint for Brugada ablation in the absence of drug challenge. Fragmentation mapping appeared to reproducibly confirm complete substrate elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.